• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Xpose——一种基于S-PLUS的用于NONMEM的群体药代动力学/药效学模型构建辅助工具。

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

作者信息

Jonsson E N, Karlsson M O

机构信息

Department of Pharmacy, Uppsala University, Sweden.

出版信息

Comput Methods Programs Biomed. 1999 Jan;58(1):51-64. doi: 10.1016/s0169-2607(98)00067-4.

DOI:10.1016/s0169-2607(98)00067-4
PMID:10195646
Abstract

The building of population pharmacokinetic/pharmacodynamic (PK/PD) models is a time consuming and complicated task. This is partly due the lack of specialized tools for the visualization and exploration requirements of this type of analysis. In this paper we present Xpose, a model building aid for population PK/PD analysis using NONMEM, which simplifies the task of producing documentation, data set checkout plots, goodness of fit plots and graphical model comparison. It also facilitates covariate model building by the use of stepwise generalized additive modeling (GAM), bootstrap of the GAM analyses and tree based modeling. The plots and analyses are presented in the form of a text based menu system and the only thing the user has to do is to make NONMEM produce one or more table files named in a specific way.

摘要

构建群体药代动力学/药效学(PK/PD)模型是一项耗时且复杂的任务。部分原因在于缺乏针对此类分析的可视化和探索需求的专业工具。在本文中,我们介绍了Xpose,一种用于使用NONMEM进行群体PK/PD分析的模型构建辅助工具,它简化了生成文档、数据集检查图、拟合优度图和图形模型比较的任务。它还通过使用逐步广义相加模型(GAM)、GAM分析的自助法和基于树的建模来促进协变量模型构建。这些图和分析以基于文本的菜单系统形式呈现,用户唯一要做的就是让NONMEM生成一个或多个以特定方式命名的表格文件。

相似文献

1
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.Xpose——一种基于S-PLUS的用于NONMEM的群体药代动力学/药效学模型构建辅助工具。
Comput Methods Programs Biomed. 1999 Jan;58(1):51-64. doi: 10.1016/s0169-2607(98)00067-4.
2
Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.构建群体药代动力学-药效学模型。I. 协变量效应模型。
J Pharmacokinet Biopharm. 1992 Oct;20(5):511-28. doi: 10.1007/BF01061469.
3
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.群体药代动力学-药效学分析中逐步协变量模型构建策略的比较
AAPS PharmSci. 2002;4(4):E27. doi: 10.1208/ps040427.
4
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.群体药代动力学/药效学分析中模型构建策略概述:2002 - 2004年文献调查
Br J Clin Pharmacol. 2007 Nov;64(5):603-12. doi: 10.1111/j.1365-2125.2007.02975.x. Epub 2007 Aug 15.
5
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.复杂药代动力学和药效学模型的群体分析方法及软件综述,并附实例
AAPS J. 2007 Mar 2;9(1):E60-83. doi: 10.1208/aapsj0901007.
6
Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software.Pk-fit:一款药代动力学/药效学及统计数据分析软件。
Comput Biomed Res. 2000 Oct;33(5):315-29. doi: 10.1006/cbmr.2000.1548.
7
Stability and performance of a population pharmacokinetic model.群体药代动力学模型的稳定性与性能
J Clin Pharmacol. 1997 Jun;37(6):486-95. doi: 10.1002/j.1552-4604.1997.tb04326.x.
8
A Critique of Computer Simulation Software's Used in Pharmacokinetics and Pharmacodynamics Analysis.用于药代动力学和药效学分析的计算机模拟软件之批判
Curr Clin Pharmacol. 2018;13(4):216-235. doi: 10.2174/1574884713666181025144845.
9
An Evolutionary Search Algorithm for Covariate Models in Population Pharmacokinetic Analysis.群体药代动力学分析中协变量模型的一种进化搜索算法。
J Pharm Sci. 2017 Sep;106(9):2407-2411. doi: 10.1016/j.xphs.2017.04.029. Epub 2017 Apr 25.
10
Automated covariate model building within NONMEM.NONMEM 中的自动协变量模型构建。
Pharm Res. 1998 Sep;15(9):1463-8. doi: 10.1023/a:1011970125687.

引用本文的文献

1
Impact of Extracorporeal Membrane Oxygenation Life Support on Vancomycin Population Pharmacokinetics in Critical Illness: A Systematic Review.体外膜肺氧合生命支持对危重症患者万古霉素群体药代动力学的影响:一项系统评价
Clin Drug Investig. 2025 Aug 7. doi: 10.1007/s40261-025-01449-4.
2
Intravenous Clarithromycin in Critically Ill Adults: A Population Pharmacokinetic Study.重症成年患者静脉注射克拉霉素的群体药代动力学研究。
Antibiotics (Basel). 2025 May 30;14(6):559. doi: 10.3390/antibiotics14060559.
3
Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistant tuberculosis.
利福平耐药性结核病患儿中可分散片剂莫西沙星的群体药代动力学及给药方案
Br J Clin Pharmacol. 2025 Jun;91(6):1853-1864. doi: 10.1111/bcp.70005.
4
Global research on the utilization of population pharmacokinetic model: a bibliometric analysis from 2000 to 2024.全球人群药代动力学模型应用研究:2000年至2024年的文献计量分析
Front Pharmacol. 2025 May 12;16:1548023. doi: 10.3389/fphar.2025.1548023. eCollection 2025.
5
Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.奥曲肽长效注射剂(CAM2029)治疗肢端肥大症的群体药代动力学分析
Clin Pharmacokinet. 2025 May 26. doi: 10.1007/s40262-025-01522-3.
6
Population Pharmacokinetics of Alfentanil in Children.阿芬太尼在儿童中的群体药代动力学
J Clin Pharmacol. 2025 May 16. doi: 10.1002/jcph.70044.
7
Model-informed drug development of novel ROCK2 inhibitor TDI01: population pharmacokinetic study and simulation.新型ROCK2抑制剂TDI01的模型引导药物研发:群体药代动力学研究与模拟
Front Pharmacol. 2025 Mar 4;16:1477607. doi: 10.3389/fphar.2025.1477607. eCollection 2025.
8
Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistant tuberculosis.利福平耐药性结核病患儿中可分散片剂莫西沙星的群体药代动力学及给药方案
Br J Clin Pharmacol. 2025 Jun;91(6):1853-1864. doi: 10.1002/bcp.70005. Epub 2025 Feb 17.
9
Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV.在现实世界的HIV感染者中,口服和长效肌肉注射利匹韦林后的群体药代动力学。
Front Pharmacol. 2024 Nov 15;15:1437400. doi: 10.3389/fphar.2024.1437400. eCollection 2024.
10
Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies.托法替布在活动性银屑病关节炎中的暴露-反应分析:两项3期研究的结果
J Clin Pharmacol. 2025 Mar;65(3):369-377. doi: 10.1002/jcph.6147. Epub 2024 Oct 25.